Abstract
Early studies on high-dose therapy followed by autologous bone marrow transplantation demonstrated the safety and efficacy of this approach in non-Hodgkin’s lymphoma (NHL). As the procedure became easier and safer with the introduction of peripheral blood progenitor cells instead of marrow, the popularity of this procedure declined. In the last decade, autologous hematopoietic stem cell transplantion has played an important role in front-line and salvage treatments of indolent and aggressive NHL.
References
1.
Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1547.
2.
Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin’s lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994;12:2543–2549.
3.
Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s Iymphoma: final analysis of the prospective LNH-87-2 protocol – a Group d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 2000;18:3025–3031.
4.
Reyes F, Lepage E, Morel P, et al: Failure of first-line inductive high dose chemotherapy in poor risk patients with aggressive lymphoma: updated results of the randomised LHN93-2 study. Blood 1997;90:594–599.
5.
Kluin-Nelemans, Zagonel V, Anastasopoulou A, et al: Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s Iymphoma: randomised phase III EORTC study. J Natl Cancer Inst 2001;93:22–28.
6.
Santini G, Salvagno L, Leoni T, et al: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective trial by the Non-Hodgkin’s Lymphoma Cooperative study group. J Clin Oncol 1998;16:2796–2802.
7.
Linch DC, et al: A randomised trial of CHOP × 6–8 vs. CHOP × 3 + BEAM + ASCT in 457 patients with poor prognosis histologically aggressive non-Hodgkin’s lymphoma. 8th Int Conf on Malignant Lymphoma, Lugano, 2002.
8.
Gianni AM, Bregni M, Siena S, et al: High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290–1296.
9.
Martelli M, Vignetti M, Zinzani PL, et al: High dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: a pros pective randomized Italian multicenter study. J Clin Oncol 1996;14:534–539.
10.
Verdonck LF, van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 1995;332:104–110.
11.
Milpied N, Deconinck E, Gaillard F, et al: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2005;350:1287–1295.
12.
Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235–242.
13.
Pfreundschuh M, Truemper L, Gill D, et al: First analysis of the completed Mabthera International (MinT) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI = 0 and no bulky disease. Blood 2004;104:48a.
14.
Philip T, Armitage JO, Spitzer G, et al: High dose therapy and ABMT after failure of conventional chemotherapy in adults with intermediate grade or high grade NHL. N Engl J Med 1987;316:1493–1498.
15.
Petersen FB, Appelbaum FR, Hill R, et al: Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990;8:638–647.
16.
Vose JM, Anderson JR, Kessinger A, et al: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 1993;11:1846–1851.
17.
Mills W, Chopra R, McMillan A, et al: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 1995;13:588–595.
18.
Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al: Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 1996;2:76–85.
19.
Caballero MD, Rubio V, Rifon J, et al: BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997;20:451–458.
20.
Rapoport AP, Lifton R, Constine LS, et al: Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997;19:883–890.
21.
Stiff PJ, Dahlberg S, Forman SJ, et al: Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens – a Southwest Oncology Group trial. J Clin Oncol 1998;16:48–55.
22.
Popat U, Przepiork D, Champlin R, et al: High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 1998;16:63–69.
23.
Zinzani PL, Tani M, Gabriele A, et al: High-dose therapy with autologous transplantation for aggressive non-Hodgkin’s lymphoma: the Bologna experience. Leuk Lymphoma 2004;45:321–326.
24.
Shipp MA, Abeloff MD, Antman KH, et al: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of the jury. J Clin Oncol 1999;17:423–429.
25.
Hahn T, Wolff SN, Czuczman M, et al: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2001;7:308–331.
26.
Freedman AS, Gribben JG, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996;88:2780–2786.
27.
Horning SL, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001;97:404–409.
28.
Ladetto M, Corradini P, Vallet S, et al: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002;100:1559–1565.
29.
Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004;104:2667–2674.
30.
Sebban C, Belanger C, Brousse N, et al: Comparison of CHVP + Interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: Results of the randomised GELF 94 Trial (GELA study group). Blood 2003;102:354a.
31.
Apostolodis L, Gupta RK, Grenzelias, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up. J Clin Oncol 2000;18:527–536.
32.
Miller JS, Arthur DC, Litz CE, et al: Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994;83:3780–3786.
33.
Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 1995;13:140–147.
34.
Rohatiner AZ, Johnson PW, Price CG, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994;12:1177–1185.
35.
Haas R, Moos M, Karcher A, et al: Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1994;12:1685–1692.
36.
Cervantes F, Shu XO, McGlave PB, et al: Autologous bone marrow transplantation for non-transformed low grade non-Hodgkin’s lymphoma. Bone Marrow Transplant 1995;16:387–392.
37.
Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257–3262.
38.
Schouten TC, Raemaekers JJ, Kluin-Nelemans HC, et al: High-dose therapy followed by bone marrow transplantation for relapsed follicular non-Hodgkin’s lymphoma. Ann Hematol 1996;73:273–277.
39.
Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1997;15:445–450.
40.
Weaver CH, Schwartzberg L, Rhinehart S, et al: High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma. Bone Marrow Transplant 1998;21:383–389.
41.
Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325–3333.
42.
Brice P, Simon D, Bouabdallah R, et al: High-dose therapy with autologous stem cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000;11:1585–1590.
43.
Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H: Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 2000;65:17–22.
44.
Vaso MT, Martin S, Hohaus S, et al: Prognostic factors for the clinical outcome of patients with follicular lymphoma folIowing high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 2000;25:957–964.
45.
Cao TM, Horning S, Negrin RS, et al: High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001;7:294–301.
46.
Schouten HC, Oian W, Kvaloy S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: Results from the randomized European CUP Trial. J Clin Oncol 2003;21:3918–3927.
47.
Haas R, Brittinger G, Meusers P, et al: Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996;10:1975–1981.
48.
Blay JY, Sebban C, Surbiguet C, et al: High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: A single center experience on 18 patients. Bone Marrow Transplant 1998;21:51–56.
49.
Freedman AS, Neuberg D, Gribben JG, et al: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998;16:13–18.
50.
Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749–755.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
